Myeloma and Related Diseases Registry (MRDR)

Helping clinicians and hospitals to provide the best possible care to people with multiple myeloma and related diseases.

View our 2024 Annual Report Here

This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.

What is the registry?

Learn about how the registry works and the data we collect.
Benefits

Participation in the registry provides advantages for sites and patients.
About our projects

Find out about MRDR projects and how registry data is being used.
8317

Patients accrued

5757

Patients with multiple myeloma

60

Number of approved sites

773

M1000 Biobank participants

Latest news

MRDR Annual Breakfast Meeting 2025
02 Sep 2025

Registration is now open for the MRDR Annual Breakfast Meeting at Blood/ISBT 2025

Read more
Rare Disease Day 2025
19 Feb 2025

Rare Disease Day is next week on Friday 28th February!

Read more
MRDR reaches 8,000 patients!
06 Feb 2025

Read more
New MRDR Publication
08 Nov 2024

An MRDR paper investigating the presence of 1q21 gain and amplification on outcomes in Daratumumab-treated MM patients has now been published!

Read more

Participating organisations